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Abstract
Hematopoietic stem cells (HSCs) have the ability to self-renew and give rise to all lin-
eages of blood cells while remain the capacity of regenerative in hematopoiesis. As the 
only stem cell type in routine clinical use, HSCs can be isolated from bone marrow, 
peripheral blood and umbilical cord blood. Stem cells transplantation is mainly used in 
HSCs while the trans-differentiation ability broadens the research of HSCs in regenera-
tive medicine. Here, we focus on the current view on hematopoiesis and beyond and 
summarize the clinical application and the regulation of the fate of HSCs. We intend to 
outline recent advances in the human HSCs research area and review the characteristic 
of HSCs from definition through development to their clinical applications and future 
prospect.
Keywords: hematopoietic stem cells, stem cell niche, migration, transplantation, 
regenerative medicine, clinical application, bone marrow, microenvironment, 
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1. Introduction
Hematopoietic stem cells (HSCs) identification was confirmed in the 1950s after the first suc-
cessful transplant was performed by Thomas et al. [1]. This transplantation involved identical 
twins, one of whom had leukemia. In 1968, the first major landmark in HSCs transplanta-
tion occurred with successful allogeneic transplantations [2]. In 1988, Irving Weissman et al. 
developed reliable methods to identify HSCs population based on a set of protein markers on 
the surface of mouse blood cells with flow cytometry and fluorescence-activated cell sorting 
(FACS) [3]. The technologic advances on HSCs researches, FACS and methods for in vitro 
assays have extended to the whole field of stem cell researches, such as embryonic stem cells, 
induced pluripotent stem cells, adult stem cells and cancer stem cells, which directly lead 
to fast forward the translational applications of stem cell. Four years later, Weissman lab 
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proposed a comparable set of markers for the human stem cells [4]. Conceptually, human 
HSCs firstly appear in the earliest embryo, then move to spleen and fetal liver and ultimately 
migrate to bone marrow (BM) [5]. The specific microenvironments existing within the BM 
area have been extensively explored, which can host HSCs and other supporting cells, then 
further organize interaction between cells and cells and cells and growth factors in order to 
sustain specific aspects of hematopoiesis, such as HSCs survival, self-renewal and differentia-
tion [6]. These special hematopoietic microenvironments are also termed as “Niche,” which 
was first proposed by Schofield in 1978 and significant progresses have gained on hemato-
poietic niche [7]. Currently, it is gradually established that the main work of hematopoietic 
microenvironments is undertaking to support hematopoiesis (Figure 1). In general, HSCs are 
mainly maintained in BM microenvironment, which can regulate the proliferation, differen-
tiation and mobilization of HSCs. Nonetheless, said developments in this field will throw 
light on hematopoietic diseases such as leukemia and aplastic anemia, rapid hematopoietic 
recovery after chemotherapy or shortening the time for hematopoietic reconstruction after 
HSCs transplantation.
2. HSCs transplantation
HSCs transplantation is most often performed for patients with malignant blood diseases, 
such as leukemia and multiple myeloma, or aplastic anemia, inherited blood disorders and 
many others. The procedure of HSCs transplantation has four steps including cell collection, 
patient preparation, cells transplantation and recovery. Allogeneic and autologous are the 
Figure 1. The model of HSCs niche. The hematopoietic niches that hematopoietic stem cells mainly reside are mainly 
located in the BM during adulthood. They are composed of complex components including HSCs and other functional 
elements such as vessels, stromal cells, ECM proteins, neural inputs and endothelial cells (ECs). Only through interaction 
with these components, HSCs can keep self-renewal and differentiation. Under the help of such “blocks,” the progenitor 
cells derived from HSCs locating at the inner surface of BM migrate to blood vessels at the center of the BM cavity when 
they differentiate into mature blood cells. Reprinted by permission from the publisher.
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two main types of HSCs transplantation. Allogeneic HSCs are derived from a matched donor, 
whereas autologous HSCs are isolated from the patients. After cell collection, patients need 
chemotherapy, with or without radiation to destroy the hematopoietic function and make 
space for the transplant. Transplantation will be proceeded with intravenous injection after 
patient preparation. Recovery after cells transplant can last weeks to months.
However, HSCs transplantation remains a dangerous procedure with many possible compli-
cations; it is reserved for patients with life-threatening diseases. Infection and graft-versus-
host disease (GVHD) are major complications of allogeneic HSCs transplantation. A major 
challenge in improving the success of allogeneic hematopoietic stem cells in the treatment of 
leukemia is to minimize GVHD reactions and simultaneously optimize graft-versus-leukemia 
(GVL) reactions. Therefore, it remains to see the era of predicting biological behavior based 
on the knowledge of molecular mechanisms in HSCs transplantation, and how host responds 
to the transplanted HSCs.
3. Migration of HSCs into and out of marrow and tissues
The progress of stem cell research, along with technological innovation, has brought research-
ers to focus on the potential role of stem cells in regenerative medicine. Bone marrow-derived 
stem cells, including HSCs, can potentially restore the function of diseased or damaged tis-
sues/organs, offering significant potential for regenerative medicine [8]. Moreover, trans-dif-
ferentiation or plasticity of HSCs in repair or rejuvenation of tissues and organs have drawn 
focused attention [9]. It has been proposed that HSCs continue to migrate via the blood stream 
throughout adulthood. Continuous migration of HSCs among the organs and circulation 
likely fill the empty or damaged niches and contribute to the maintenance of normal organ 
functions and restoring degraded tissues [5, 6, 8–10] (Figure 2). Both tissue repair and regen-
eration are thought to involve resident cell proliferation as well as the selective recruitment 
of circulating HSCs [11]. Moreover, differentiation of HSCs into cardiomyocytes also give 
rise to thoughts that the HSCs population is critical for myocardium homeostasis and these 
repair progress after injury via reprogramming the phenotype of HSCs to induce cardiomyo-
cyte renewal [9]. Furthermore, other HSCs transplantation models have shown that HSCs 
could transdifferentiate into liver, brain, skeletal muscle, kidney, intestine and many others 
[9]. Several studies have shown a constant exchange of HSCs between bone and peripheral 
blood and it has been estimated that up to 400 HSCs circulate in the blood of a mouse at any 
one time [12] (Figure 2). The efficiency of BM cell-based therapy to augment the recovery 
from damaged tissues depends on not only sufficient amount of stem cells but also efficient 
delivery of these cells to the desired target tissue. HSCs are unique in their ability to migrate 
to various sites, ensuring the safety and integrity of their regenerative potential.
Currently, there are some clinical trials about bone marrow-derived stem cells in clinical trial 
(clinicaltrials.gov). A number of trials are focused on the safety and efficacy of autologous/
allogeneic stem cell transplantation for treatment of a diverse array of diseases (Table 1). 
The results of these trials have confirmed that HSCs injection is safe and has the capability 
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to improve target tissue/organ function. However, the number of trafficking HSCs in blood 
stream is at an extremely low level [13]. Promoting BM stem cell mobilization is a common 
strategy to augment the cellular yield of peripheral blood apheresis for clinical stem cell trans-
plantation, and a similar approach has been suggested to increase the number of circulating 
cells available for homing to the damaged sites following injury [10–14]. The self-renewal and 
trans-differentiation capacities of BM stem cells are worthless unless their migration to target 
tissues can be appropriately orchestrated [15].
Figure 2. Maintenance and trafficking of HSCs in various tissues and organs. Besides the initial findings that HSCs 
are located in bone marrow, this extremely rare population of cells is also detected in other adult tissues (e.g. brain, 
kidney, skeletal muscle and pancreas). HSCs could be a potential back-up source for restoring the function of diseased 
or damaged tissues/organs. Reprinted by permission from the publisher.
Clinical study Study 
phase
Source Procedure Year Disease Reference
NCT01183728 I, II Autologous Articular injection 2014 Knee osteoarthritis [18]
NCT01775774 I Allogeneic Intravenous injection 2015 Acute respiratory 
distress syndrome
[19]
NCT00768066 I, II Autologous Transendocardial 
injection
2013 Ischemic heart failure [20]
NCT00629018 II Autologous Intracoronary injection 2013 Dilated 
cardiomyopathy
[21]
NCT01363401 I, II Autologous Intrathecal injection 2013 Amyotrophic lateral 
sclerosis
[22]
Table 1. Completed bone marrow-derived stem cell-based clinical trials in regenerative medicine registered at https://
clinicaltrials.gov/
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4. Present state of art and limitations
Allogeneic and autologous HSCs transplantation is mainly used in in the treatment of hema-
tologic and genetic conditions. According to the data collected by Worldwide Network for 
Blood & Marrow Transplantation (WBMT), 953,651 HSC transplantations (553,350 [58%] 
autologous and 400,301 [42%] allogeneic) were reported by 1516 transplant centers from 75 
countries [16] between January 1, 2006 and December 31, 2014. The use of HSC transplanta-
tions increased from the first transplant in 1957 to almost 1 million by December, 2012. This 
result suggests an increasing need of HSCs in clinical application. However, there are a num-
ber of challenges and limitations still confront the clinical application of HSC transplanta-
tion, such as limited HSC numbers in donor grafts and availability of HLA-matched donors. 
Besides, many complications such as infection, veno-occlusive disease (VOD) and GVHD 
after HSCs transplantation also influence quality of the patients’ life, which limits its use to 
conditions that are themselves life-threatening. The challenges in the HSCs transplantation 
field are big for increasing cell survival rate after engraftment and decreasing major complica-
tions associated with a high treatment-related mortality in the recipient including infections 
(sepsis), GVHD and the development of new malignancies.
5. Future perspectives
HSCs are the best characterized adult stem cell type, which are mainly used in hematological 
disease. Several studies on HSCs biology and transplantation in their clinical therapy. Over 
recent years, it came as a great surprise that several models had shown that the trans-differ-
entiation of HSCs may cross germ-layer boundaries and differentiate into some mature cells 
from different layer, which suggest that somatic stem cells, including HSCs, may serve as a 
cell source for tissue engineering or cell therapy [17]. Besides, induced pluripotent stem (iPS) 
cell-derived HSCs could be an ideal source for resolving current limitations related to HSCs 
transplantation. The use of iPS cells to generate HSCs is of considerable therapeutic interest, 
as traditional HSCs transplantation is limited by the lack of compatible donors, a high risk of 
engraftment failure and GVHD. In conclusion, these efforts could expand the use of HSCs in 
several different diseases, reduce the incidence of complications and increase the size of the 
beneficiary populations.
6. Conclusion
In conclusion, HSCs are somatic stem cells, which are vital in cell-based clinical application. 
After years of research, HSCs transplantation and therapy from an experimental concept to a 
safe clinical cure for numbers of diseases. With further study in the trans-differentiation and 
niche of HSCs, there is no doubt that HSCs have great prospects for application in stem cell 
transplantation and regenerative medicine.
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